PT986387E - Inibidores de farnesil transferase em combinacao com inibidores de hmg coa redutase para o tratamento do cancro - Google Patents

Inibidores de farnesil transferase em combinacao com inibidores de hmg coa redutase para o tratamento do cancro

Info

Publication number
PT986387E
PT986387E PT98921688T PT98921688T PT986387E PT 986387 E PT986387 E PT 986387E PT 98921688 T PT98921688 T PT 98921688T PT 98921688 T PT98921688 T PT 98921688T PT 986387 E PT986387 E PT 986387E
Authority
PT
Portugal
Prior art keywords
inhibitors
farnesil
combination
cancer treatment
transferase
Prior art date
Application number
PT98921688T
Other languages
English (en)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT986387E publication Critical patent/PT986387E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT98921688T 1997-06-16 1998-06-05 Inibidores de farnesil transferase em combinacao com inibidores de hmg coa redutase para o tratamento do cancro PT986387E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
PT986387E true PT986387E (pt) 2003-06-30

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98921688T PT986387E (pt) 1997-06-16 1998-06-05 Inibidores de farnesil transferase em combinacao com inibidores de hmg coa redutase para o tratamento do cancro

Country Status (37)

Country Link
EP (1) EP0986387B1 (pt)
JP (1) JP3713051B2 (pt)
KR (1) KR100392573B1 (pt)
CN (1) CN1259868A (pt)
AP (1) AP9801261A0 (pt)
AR (1) AR013090A1 (pt)
AT (1) ATE235905T1 (pt)
BG (1) BG103946A (pt)
BR (1) BR9810616A (pt)
CA (1) CA2294399C (pt)
CO (1) CO4950607A1 (pt)
DE (1) DE69812933T2 (pt)
DK (1) DK0986387T3 (pt)
DZ (1) DZ2518A1 (pt)
EA (1) EA199901043A1 (pt)
ES (1) ES2196559T3 (pt)
GT (1) GT199800081A (pt)
HN (1) HN1998000091A (pt)
HR (1) HRP980328B1 (pt)
HU (1) HUP0004624A3 (pt)
ID (1) ID23014A (pt)
IL (1) IL132765A0 (pt)
IS (1) IS5259A (pt)
MA (1) MA24569A1 (pt)
NO (1) NO996206L (pt)
NZ (1) NZ500662A (pt)
OA (1) OA11231A (pt)
PA (1) PA8453601A1 (pt)
PE (1) PE82899A1 (pt)
PL (1) PL337651A1 (pt)
PT (1) PT986387E (pt)
SK (1) SK169699A3 (pt)
TN (1) TNSN98088A1 (pt)
TR (1) TR199903074T2 (pt)
UA (1) UA57081C2 (pt)
WO (1) WO1998057633A1 (pt)
ZA (1) ZA985182B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK16742000A3 (sk) 1998-05-12 2001-07-10 Warner-Lambert Company Kombinácie proteínovej farnesyltransferázy a inhibítorov hmg coa reduktázy a ich použitie pri liečbe rakoviny
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
EP1555021A1 (en) * 2004-01-16 2005-07-20 National Health Research Institutes Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids

Also Published As

Publication number Publication date
ID23014A (id) 1999-12-30
HUP0004624A2 (hu) 2001-10-28
ES2196559T3 (es) 2003-12-16
AU7445998A (en) 1999-01-04
PA8453601A1 (es) 2000-05-24
DK0986387T3 (da) 2003-07-14
JP3713051B2 (ja) 2005-11-02
BG103946A (bg) 2000-07-31
TNSN98088A1 (fr) 2005-03-15
PE82899A1 (es) 1999-08-26
CO4950607A1 (es) 2000-09-01
IS5259A (is) 1999-11-19
UA57081C2 (uk) 2003-06-16
NO996206L (no) 2000-02-15
HRP980328B1 (en) 2002-06-30
DZ2518A1 (fr) 2003-02-01
HRP980328A2 (en) 1999-04-30
PL337651A1 (en) 2000-08-28
AU724676B2 (en) 2000-09-28
AR013090A1 (es) 2000-12-13
EP0986387A1 (en) 2000-03-22
AP9801261A0 (en) 1999-12-11
WO1998057633A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
CN1259868A (zh) 2000-07-12
NZ500662A (en) 2001-10-26
KR100392573B1 (ko) 2003-07-23
DE69812933D1 (de) 2003-05-08
EA199901043A1 (ru) 2000-06-26
NO996206D0 (no) 1999-12-15
EP0986387B1 (en) 2003-04-02
GT199800081A (es) 1999-12-07
KR20010013839A (ko) 2001-02-26
ZA985182B (en) 1999-12-17
CA2294399A1 (en) 1998-12-23
HN1998000091A (es) 1999-09-29
DE69812933T2 (de) 2003-11-06
HUP0004624A3 (en) 2002-11-28
BR9810616A (pt) 2000-09-12
OA11231A (en) 2003-05-26
TR199903074T2 (xx) 2000-05-22
ATE235905T1 (de) 2003-04-15
MA24569A1 (fr) 1998-12-31
JP2000513031A (ja) 2000-10-03
IL132765A0 (en) 2001-03-19
SK169699A3 (en) 2000-06-12

Similar Documents

Publication Publication Date Title
PT781136E (pt) Compostos e processos para o tratamento do cancro
ID26987A (id) Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
IT1271508B (it) Chiodo endomidollare bloccato adatto in particolare per omero
AU7696098A (en) Substance p inhibitors in combination with nmda-blockers for treating pain
BR9705106A (pt) Chapa de aço eletromagnético com granulação orientada
AU7472798A (en) Cox-2 inhibitors in combination with nmda-blockers for treating pain
PT986387E (pt) Inibidores de farnesil transferase em combinacao com inibidores de hmg coa redutase para o tratamento do cancro
DE69809483D1 (de) Leitende Rolle mit niedriger Härte
FI960658L (fi) Uudet bis-naftalimidit syövän hoitamiseksi
PT1047665E (pt) Inibidores de metaloproteases de matriz
PT957456E (pt) Dispositivo de devolucao para mecanismos de pagamento
BR7501644U (pt) Cavalete para automóveis em geral
SI0986387T1 (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
GB9903035D0 (en) Treating cancer
GB2334579B (en) Treating cancer
BR7401022U (pt) Disposição introduzida em presilha auto-ajustável
BR7702301U (pt) Dispositivo de proteção para fogões em geral
BR7400382U (pt) Disposição introduzida em batoque corta-fluxo para frascos diversos
BR7701383U (pt) Disposição introduzida em capa de proteção
BR7701833U (pt) Disposição introduzida em envelope para correspondencia
BR7700356U (pt) Aperfeiçoamento em trava para capa de autos
BR7603145U (pt) Painel publicitário para bancas de revistas
BR9400300A (pt) Aperfeiçoamento introduzido em luminária de embutir
BR7301218U (pt) Disposicao introduzida em protetor para calcinha
BR7701343U (pt) Aperfeiçoamento introduzido em suportes